drugset / Trial / NCT00891709

LEO 29102 Single and Multiple Dose Study by Dermal Application

NCT00891709

Phase 1 Completed 64 enrolled LEO Pharma
RandomizedParallel-groupTriple-blindOther

Summary

The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy male subjects. The study is divided into one single dose part followed by a multiple dose part.

Timeline

Start
2009-03
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LEO 29102 Unknown 2.5 unknown Other

Indications